HSPA5 and atherosclerosis: Recent pilot data presented at the European Respiratory Society Congress highlight the potential benefit of belimumab in CVD.33 The group shows that following treatment with belimumab, there is a reduction in circulating anti-GRP78 (glucose-regulated protein 78) levels, which are associated with severe chronic obstructive pulmonary disease and the development of atherosclerosis, with no increase in infections.